Mal-PEG4-bis-PEG4-propargyl

Cat. No.: HY-130973: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Mal-PEG4-bis-PEG4-propargyl is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Mal-PEG4-bis-PEG4-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

For research use only. We do not sell to patients.

Mal-PEG4-bis-PEG4-propargyl Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Linker Isoform Specific Products:

View All Isoforms

Cleavable Linker Non-cleavable Linker Acid Cleavable Linker Disulfide Cleavable Linker Protease Cleavable Linker Glycosidase Cleavable Linker Phosphatase Cleavable Linker

Biological Activity
Purity & Documentation
References
Customer Review

Description

Mal-PEG4-bis-PEG4-propargyl is a cleavable 8 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)^[1]. Mal-PEG4-bis-PEG4-propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

IC₅₀ & Target

Cleavable Linker

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1060.19

Formula

C₄₉H₈₁N₅O₂₀

SMILES

O=C(CCOCCOCCOCCOCCNC(CCN1C(C=CC1=O)=O)=O)NC(COCCC(NCCOCCOCCOCCOCC#C)=O)COCCC(NCCOCCOCCOCCOCC#C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]